Cambrex Corporation And Cytori Therapeutics, Inc. Enter Into Collaboration To Provide Adipose Derived Stem Cell Research Products

WALKERSVILLE, Md., and SAN DIEGO, June 13 /PRNewswire-FirstCall/ -- Cambrex Bio Science Walkersville, Inc., a subsidiary of Cambrex Corporation (NYSE: CBM - News), and Cytori Therapeutics (Nasdaq: CYTX - News) announced today that they have entered into a strategic marketing agreement to provide adipose-derived stem cell products globally for use in basic and translational bioresearch.

MORE ON THIS TOPIC